OM:ORXPharmaceuticals
Orexo (OM:ORX) Heads Into Earnings With Ongoing Losses and Sector-Low 1.8x Price-To-Sales Ratio
Orexo (OM:ORX) remains unprofitable, with losses increasing at an average rate of 3.7% per year over the past five years. Revenue is forecast to grow by 2.5% annually, trailing behind the broader Swedish market’s 3.9% average growth. While the company’s slower growth and ongoing losses present real challenges for investors, the current Price-To-Sales Ratio of 1.8x stands out as a notable value play within the European pharmaceuticals sector.
See our full analysis for Orexo.
Next up, we’ll see...